HK Stock Market Move | HENLIUS (02696) rose by more than 5% in early trading. The company will authorize the rights of Hanshu to Japan to Weicai. The total transaction amount is approximately 3.88 billion US dollars.

HENLIUS (02696) rose more than 5% in early trading, as of the time of writing, it rose 4.64% to 63.15 Hong Kong dollars, with a turnover of 32.6222 million Hong Kong dollars. In terms of news, HENLIUS announced that the company will grant the Japanese rights of the monoclonal antibody HANSUMAB (Sulforidex monoclonal antibody) to WEIKE. WEIKE will pay HENLIUS a first payment of 75 million US dollars, and on this basis, pay a regulatory milestone payment of no more than 80.01 million US dollars, as well as a sales milestone payment of no more than 233 million US dollars. In addition, HENLIUS will also receive a double-digit percentage of sales commission based on product sales. It is reported that Sulforidex monoclonal antibody is an innovative anti-PD-1 monoclonal antibody independently developed by HENLIUS. In China, Sulforidex monoclonal antibody has been approved for multiple indications, including squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsqNSCLC), and esophageal squamous cell carcinoma (ESCC). In the European Union, Sulforidex monoclonal antibody has been approved for the indication of ES-SCLC and has become the world's first anti-PD-1 monoclonal antibody for first-line treatment of ES-SCLC.